NGEN vs NGNE

NervGen Pharma Corp. vs Neurogene Inc. — Valuation Comparison 2026

NGEN

Biotechnology
NervGen Pharma Corp.
Quality
3.1
out of 10
Value Trap
Price
$2.08
Last close
Models
6/13
Active
VS

NGNE

Biotechnology
Neurogene Inc.
Quality
5.2
out of 10
Value Trap
18
SAFE
Price
$27.50
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NGEN Fair ValueNGEN Upside NGNE Fair ValueNGNE Upside
Bayesian DCF Intrinsic $0.64 -69.5% $11.44 -58.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.09 -95.6% $16.56 -39.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NGEN vs NGNE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NGEN vs NGNE — Which Stock Is More Undervalued?

NGNE scores higher with a 5.2/10 quality rating vs NGEN's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NervGen Pharma Corp. (NGEN) and Neurogene Inc. (NGNE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NGEN currently trades at $2.08 with a QOC of 3.1/10, while NGNE trades at $27.50 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).